Loading patent…
AssigneeMacfarlane Burnet Institute for Medical Research and Public Health Limited
InventorsHeidi Drummer, Kathleen McCaffrey, Pantelis Poumbourios
Estimating the term…
A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof. A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomelic HCV E2 polypeptide, the method comprising expressing a polypeptide in a host cell and isolating the expressed product, wherein the polypeptide is an HCV E2 polypeptide including a receptor binding variant, and wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597.
A composition, comprising a modified hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a modified receptor binding variant, comprising at least four mutated or disrupted cysteines selected from among C581, C585, C652, C677, C494, C486, C459, C452, C564, C597, C569 and C620, wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding.
A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomeric HCV E2 polypeptide, the method comprising:
Dependencies are inferred from the claim text.